Compare GSK plc (GSK) vs Paycom Software Inc (PAYC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Paycom Software Inc — how do they compare? GSK plc trades at $52.34 (market cap $101.34B), while Paycom Software Inc trades at $148.53 (market cap $6.75B). The key difference: GSK plc is far larger — about 15× Paycom Software Inc's market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | PAYC | |
|---|---|---|
Market Cap | $101.34B | $6.75B |
Sector | Health | Technology |
52-Week High | $61.18 | $238.80 |
52-Week Low | $36.20 | $113.59 |
Enterprise Value | $121.95B | $7.36B |
Dividend Yield | 3.49% | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Paycom Software (PAYC) trades at $148.20, up 3.15% today, with a bullish technical signal from moving averages and a consensus analyst price target of $151.00. The company reported strong Q1 2026 earnings of $3.15 per share, beating estimates, and maintains robust profitability with a 22.44% net income margin. Recent developments include the launch of an asset management tool and new board appointments, highlighting ongoing innovation and governance strength.
The outlook for PAYC is positive, supported by consistent revenue growth, high margins, and strategic product expansions. Key risks include competitive pressures in HCM software and execution challenges. With a balanced analyst rating split and solid institutional backing, the stock presents a moderate growth opportunity, though investors should monitor upcoming Q2 2026 earnings for further direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →
